Mode
Text Size
Log in / Sign up
Phase 2 N=676 Randomized Double-blind Treatment

MK3207 for Treatment of Acute Migraines (3207-005)

Migraine

Enrolled (actual)
676
Serious AEs
0.4%
Results posted
Nov 2010
Primary outcome: Primary: Pain Freedom (PF) — 13; 4; 5; 16 Participants — p=<0.001

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
MK3207- 2.5 mg (Drug); MK3207- 5 mg (Drug); MK3207- 10 mg (Drug); MK3207- 20 mg (Drug); MK3207- 50 mg (Drug); MK3207- 100 mg (Drug); Comparator: placebo (unspecified) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Merck Sharp & Dohme LLC
Primary completion
Jan 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Freedom (PF)
13; 4; 5; 16; 12; 14 <0.001 sig
SECONDARY
Pain Relief (PR)
48; 15; 19; 36; 36; 41 <0.001 sig
SECONDARY
Absence of Photophobia
51; 10; 15; 32; 27; 32 <0.001 sig
SECONDARY
Absence of Phonophobia
57; 12; 18; 35; 35; 38 <0.001 sig
SECONDARY
Absence of Nausea
79; 19; 25; 44; 42; 44 0.007 sig
SECONDARY
Sustained Pain Freedom (SPF)
10; 4; 2; 13; 10; 12 <0.001 sig

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Eligibility Criteria

Inclusion Criteria

  • Men and Women from 18 to 65 years of age
  • 1+ year history of migraine that typically last from 4 to 72 hours if untreated
  • Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months
  • Not pregnant or planning to become pregnant in next 6 months

Exclusion Criteria

  • Pregnant or breast-feeding, or planning to become pregnant in next 6 months
  • Cannot distinguish migraine attacks from tension type headaches
  • Migraines are mild or resolve without medication in less than 2 hours
  • More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months
  • Basilar type or hemiplegic migraine headaches
  • More than 50 years old when migraines began
  • History of cardiovascular disorder within last 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00712725). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search